Glenmark Pharma Q2 FY27 Revenue Up ~20% YoY to ₹4,247 Crore; North America Core Business Grows 31%
Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of ₹4,247 crore, up ~20% YoY. India business grew ~14%, North America core business ~31%, EU 6.2%, and Emerging Markets 33.2%. EBITDA was ₹863.8 crore with a 20.3% margin. Chairman Glenn Saldanha highlighted strong base business performance and progress in innovative pipelines, with first oncology launch expected by FY27.
The announcement details significant revenue growth and improved profitability, along with strategic updates on product launches and pipeline development. These factors are material to investors and indicate strong business performance and future potential.
The company reported strong year-on-year revenue growth, improved regional performance, and positive commentary from the Chairman regarding business resilience and future growth drivers. Updates on R&D and pipeline advancements also contribute to a positive sentiment.
Glenmark Pharmaceuticals Limited announced its financial results for the second quarter and half-year ended September 30, 2026 (Q2 FY27 and H1 FY27). The company reported consolidated revenue of ₹4,247.3 crore (₹42,473 million) for Q2 FY27, marking a like-for-like year-on-year growth of approximately 20%.
Key regional highlights for Q2 FY27 include a ~14% growth in the India business, a significant ~31% growth in North America's core business (excluding deferred out-licensing income recognition for ISB 2001), 6.2% growth in the EU business, and a robust 33.2% growth in Emerging Markets.
Profitability metrics for the quarter show consolidated R&D expenses at ₹344.9 crore (₹3,449 million), EBITDA at ₹863.8 crore (₹8,638 million) with an EBITDA margin of 20.3%, and adjusted Profit After Tax (PAT) at ₹485.2 crore (₹4,852 million) with an adjusted PAT margin of 11.4%.
Glenn Saldanha, Chairman and Managing Director, commented that Q2 demonstrated the strength and resilience of Glenmark’s base business. The company remains on track to deliver its FY27 guidance with continued growth in India, a strong recovery in North America supported by multiple launches, and robust performance across Emerging Markets. RYALTRIS® continues to expand internationally with a recent launch in Brazil, and the partnered innovative oncology pipeline is advancing towards commercialization, with the first launch expected by the end of FY27.
IGI, the company's innovation arm, is advancing its multispecific oncology pipeline. Phase 1 ISB 2001 data has been selected for oral presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, and an IND application for ISB 2301 is intended to be submitted by the end of CY26. The company also provided updates on other innovative assets like WINLEVI®, QINHYAYO™, TRASTUZUMAB REZETECAN, and AUMOLERTINIB, with several expected launches and filings in upcoming quarters.
The investor presentation, including these details, was enclosed with the announcement dated November 5, 2026.
What to do with a filing like this
Glenmark Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Glenmark Pharmaceuticals Limited. Read the original for the full detail.